Evogene (EVGN) Registration filing summary

Company overview and business model

• Designs novel, highly potent small molecules for drug development and ag-chemicals using ChemPass AI, a computational generative AI engine.

• Shifted strategic focus in 2025 to exclusively develop small molecule products, discontinuing other tech engines and non-core activities.

• Operates through three units: computational (ChemPass AI), pharmaceutical (novel small molecules), and agricultural (Ag Plenus subsidiary for ag-chemicals collaborations).

Financial performance and metrics

• As of December 31, 2025, cash and cash equivalents were $12.96 million (actual) and $16.06 million (pro forma).

• Total equity was $11.98 million (actual) and $11.41 million (pro forma).

• Accumulated deficit stood at $282.56 million (actual) and $284.27 million (pro forma).

Use of proceeds and capital allocation

• Will receive up to $6.35 million from warrant exercises, intended for R&D, working capital, subsidiary investments, sales and marketing, and general corporate purposes.

• May use a portion of proceeds for acquisitions or investments in complementary technologies, products, or businesses.